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ABSTRACT
Background: New generation Direct-acting antivirals (DAAs) for the treatment of chronic
hepatitis C infection have been on the market for more than 3 years since late 2013. Whether
these medications cure patients at the rates claimed in clinical trials is not clear. Furthermore, as
compliance is known to affect treatment outcomes, DAAs compliance rate is worth studying.
Methods: We analyzed the association of social-demographic, DAA use, enrollment with
Kentucky Medicaid Managed Care Organizations (MCOs) and comorbidities, and DAA
compliance in 1128 Kentucky Medicaid members treated with DAAs between August 07, 2014
and August 06, 2016.
Results: Age, MCOs, liver fibrosis or cirrhosis, the use of ribavirin as supportive treatment of
DAAs and taking more than one DAA were significant determinants of patient compliance. Age
above 60 and being enrolled with Wellcare were associated with an increase in hepatitis C
medications adherence after adjusting for all other risk factors (1.434 [1.045, 1.968] for
age >=60 in comparison to age between 50-59, 0.58 [95% CI: (0.37, 0.89)], 0.35 [95% CI: (0.21,
0.58)], 0.64 [95% CI: (0.42, 0.99)] and 0.55 [95% CI: (0.40, 0.76)] respectively for Aetna,
Anthem, Humana and Passport compared with Wellcare). In contrast, being comorbid with liver
fibrosis/cirrhosis, taking ribavirin or more than one DAA were significantly related to decreased
adherence (0.74 [0.57, 0.96], 61.6% [0.26, 0.58], 0.50 [0.29, 0.86 respectively]. Use of Sovaldi
and being comorbid with rheumatoid arthritis also had an impact without achieving significance.
Conclusion: The findings of this study can be a useful screening tool for patients with factors that
have predispositions for noncompliance. However, more studies in this area should be done to
endorse these findings before they can be translated into clinical practice.
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INTRODUCTION
It is estimated that 3.5 million persons are living with hepatitis C virus (HCV) infection
in the United States (Edlin et al, 2015). The state of Kentucky saw the highest incidence (4 per
100,000 population) of acute hepatitis C infection in US from 2010 through 2014 (Center for
Disease Control, 2014). During this time, Women of childbearing age between 15-44 who tested
positive for HCV increased by 22% nationally and greater than 200% for Kentucky (Koneru et
al, 2016). Among those acutely infected, chronic HCV (CHC) infection develops in 50-85% of
the patients, posing great challenge and pressure to the medical and public health community
(Lauer et al, 2001).
Before the development of oral, direct-acting antivirals (DAAs), the backbone of chronic
hepatitis C infection was the combination of pegylated interferon and ribavirin, which can
eradicate the virus in more than 50% of patients (Poynard et al, 2003). Interferon induces host
antiviral gene expression to inhibit virus replication, protein synthesis and assembly, along with
enhancing immune response (Feld & Hoofnagle, 2003). As a guanosine analogue, ribavirin
directly inhibits HCV replication and was found to potentiate the antiviral activity of interferon
(Feld & Hoofnagle, 2003). They affect non-specific intracellular singling pathways of HCV
replication. HCV treatment took a major step forward at the end of 2013 with the approvals of
the second-generation protease inhibitor simeprevir (Olysio) and the nucleotide polymerase
inhibitor sofosbuvir (Sovaldi). Both are DAAs and target only specific molecules and enzymes
involved in various stages of the HCV life cycle. Ever since then, concerns have been raised by
the states about the budgetary impact on Medicaid programs and beneficiary access to needed
care (CMS, 2015). As much as the Center for Medicare and Medicaid Services (CMS) is trying
to remain committed to Medicaid beneficiaries continuing to have access to needed prescribed
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medications, they also recognize the challenges that have risen with DAA HCV drugs (CMS,
2015). Limitations on treatment capacity makes it difficult to eliminate the hepatitis C virus in
the United States (Brawley et al, 2016). Currently, less than 3 percent of the state's Medicaid
beneficiaries with the disease receive treatment (Patrick 2016). For Harvoni alone, Medicaid
spending nationwide on this medication soared 22-fold in one year, from just 95 million in 2014
to $2.2 billion in year 2015 (5CMS 2016). In Kentucky, spending on Harvoni and Sovaldi in the
first two quarters of fiscal year 2016 exceeded $25 million (Medicaid.org, 2017).
For over a decade, the standard-of-care treatment for CHC has been interferon/ribavirin
combination therapy, which has a 40-50% response rate in genotype 1 CHC patients and a
response of up to 70-80% in genotype 2/3 CHC patients (Umar et al, 2013). With CHC infection
cure rates between 90%-100% using the new generation oral medications in just 12 weeks’ time
(US FDA, 2016), non-adherence is the most important risk factor for hepatitis C virus treatment
failure (Sarpel et al, 2016; American Association for the Study of Liver Diseases, 2017).
Although extensive studies have related poor adherence and outcomes with interferon and
ribavirin-based therapy (Davis et al, 2003; McHutchison et al, 2002; Younossi et al, 2015), few
studies, however, have evaluated the compliance rate of these highly effective direct-acting
antivirals (DAAs) since their approval in late 2013 in non-controlled environments. A review
published in 2014 analyzed the factors that modulate patient-driven adherence to the treatment of
HCV infection with first generation protease inhibitors telaprevir (TVR) and boceprevir (BOC).
It suggested that treatment complexity and side effects were key points for the adherence and
success of the therapy (Larrey et al, 2014). A multicenter multinational phase 3 clinical trial
discovered that a high overall adherence rate of 96.2% was achieved in 1483 patients treated
with interferon- and ribavirin-free sofosbuvir (SOF) and ledipasvir (LED) in a fixed dose
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combination therapy (Younossi et al 2016). Up to now, the magnitude of the association of noncompliance with treatment failure in patients with CHC infection is unclear, but any factors that
may potentially reduce sustained virologic response can impede the hard-earned progress the
Center for Medicare and Medicaid Services and state Medicaid agencies have made expanding
access to this expensive cure regimen (Center for Disease Control (CDC), 2012; CMS, 2016;
Gensen et al, 2014).
We performed a case control study in CHC patients enrolled in Kentucky Medicaid
population to evaluate the compliance to new DAAs and the factors associated with high
compliance. Subgroup analysis was also conducted to evaluate laboratory features and patient
characteristics associated with treatment failure. This study aimed to bridge the gap in current
hepatitis C treatment by exploring the compliance pattern in a state severely impacted by the
hepatitis C epidemic.
METHODS
Dataset
This retrospective observational study was carried out on hepatitis C patients enrolled
with Kentucky Medicaid who were treated with the new generation antiviral therapies in 114
counties in Kentucky between August 07, 2014 and August 06, 2016. Outpatient prescriptions
covered through Kentucky Medicaid were managed either with Kentucky Medicaid’s Fee for
Service (FFS) program through Magellan Health, a Pharmacy Benefit Manager, or carved out to
the Medicaid Managed Care Organizations (MCOs), including Aetna Better Health (Aetna),
Anthem Blue Cross Blue Shield (Anthem), Humana CareSource (Humana), Passport Health Plan
(Passport) and Wellcare of Kentucky (Wellcare). All 1128 patients were identified from the
Kentucky Medicaid Database by searching 11 DAA medications approved by the Food and Drug
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Administration (FDA) for use in CHC treatment: Daklinza (Daclatasvir), Epclusa
(Sofosbuvir/Velpatasvir), Harvoni (Ledipasvir/Sofosbuvir), Inciviek (Telaprevir), Olysio
(Simeprevir), Sovaldi (sofosbuvir), Technivie (Paritaprevir/Ombitasvir/Ritonavir), Viekira Pak
(Dasabuvir/Paritaprevir/Ombitasvir/Ritonavir) and Zepatier (Elbasvir/Grazoprevir). All 5613
hepatitis C related prescriptions including add-on ribavirin and interferon alpha prescriptions
were examined.
Compliance in our study was defined by the formulary metric Proportion of Days
Covered (PDC). Reported as a percentage, it measured the number of days covered by
prescriptions and divided by the number of days in the measurement period for that medication.
It is usually preferred over the use of the Medication Possession Ratio (MPR) for a more
conservative estimate of adherence (Nau, 2012). The PDC value for each member was the
average PDC value of all hepatitis C medications reimbursed through Kentucky Medicaid during
the study period. A patient was defined as “compliant” with hepatitis C treatment when the
average PDC for all medications was 100%.
The covariates obtained through each prescription entry included age (year), sex, race,
county of residence, MCO/PBM, medication, medication National Drug Code (NDC), dispensed
quantity, days of supply (days) and comorbidities. The corresponding comorbidities associated
with each member on DAA were extracted as well for risk stratification. Age was categorized
into 4 groups: ≤40, 40~49, 50~59 and ≥60. To better investigate the relationship of geographic
location and compliance, counties were rearranged into new categories based on county Beale
Code Urban-Rural Classification Scheme and Rural-Urban Continuum Codes (National Cancer
Institute (NCI), n.d.). They are relabeled as “Metro county” if Beale Codes are between 1~3,
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“Urban county” if between 4-6 and “Rural county” if between 7-9. Metro status is “1” if counties
are grouped as “Metro county” and “0” if otherwise.
All antiviral medications for hepatitis C were evaluated to investigate patient-specific
adherence. Antiviral regimen may change, therefore an additional variable called “multiple
treatment” was added to account for the variance in compliance, with a value of “1” if a member
had received more than 1 DAAs in the designated time and “0” if otherwise. As patients can be
on interferon alpha 2a and ribavirin for supportive therapy of DAAs, the use of either or both
medications were added as covariates as well.
A total of 31 types of comorbidities were captured by submission of out-patient
prescription medication claims. included cancer, cardiovascular disease and respiratory disease
among others. To make more general predictions on the impact of certain diseases on treatment
compliance, two new composite comorbidity variables were created: “cardiovascular disease
(CVD)” and “cancer”. The number and types of comorbidities related to members were
compared in two groups: compliant members and non-compliant members.
Statistical Analysis
Statistical analysis was conducted with SAS 9.4 for Windows V6.1. Comparisons were
performed using the Student t test, the Mann-Whitney-Wilcoxon test and Chi-square test in two
compliance groups. To identify the factors shaping compliance with CHC treatment, bivariate
relationships between compliance and the covariates described earlier were assessed. Covariates
with a p-value of less than 0.05, together with covariates that have been identified to impact
treatment adherence rate in previous studies, were selected into a backward stepwise multivariate logistic analysis.
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Exploratory analyses included the use of descriptive statistics. Specifically, frequencies
and percentages were examined for categorical variables-beale codes, DAAs, metro status,
gender, race, MCOs and supportive therapy, and means, standard deviations and ranges were
examined for continuous variables-age, PDC (%), number of comorbidities.
The bivariate relationship between compliance and selected patient parameters were
assessed to determine unadjusted associations. Rather than using age as an ordinal predictor, age
categories are used as the predictor of interest to add clinical importance. The same applies for
the variable “county”, as they are re-adapted based on Beale Codes and Metro Status.
Multi-variate logistic regression was used for the final model, with the possibility of
100% compliance with hepatitis C treatment as the outcome of interest. Backward elimination
with a significance level of 0.1 was carried out for this model, starting with the main effects for
all potential predictors mentioned in the Methods section.

RESULTS

A total of 1531 Medicaid members on hepatitis C treatment were identified between
August 07, 2014 and August 06, 2016. Of these patients, 395 members were excluded from the
study because they had a gap of 45 days or greater in coverage per year (n=302) (National
Committee for Quality Assurance (NCQA), 2008), died (n=8), or were only on ribavirin,
interferon alfa-2a or both (n=93), leaving 1128 active members enrolled contiguously using
DAAs.
The descriptive statistics for the members enrolled in this study are provided in Table 1.
Of the 1128 patients, 682 (60.3) had a 100% compliance rate by PDC. Comorbidities were
common with an average number of 6 for each member. The majority of patients were white
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(41.4%) male (62.5%), came from metro areas (58.7%) and used passport (40.5%) as their PBM.
They were mostly treated with Harvoni (58.6%) or Sovaldi (37.3%), together with ribavirin or
ribavirin plus interferon for supportive care.
Table 1. Summary of Descriptive Statistics for Medicaid Members Treated with DAAs between
August 07, 2014 and August 06, 2016
Variable

Pertinent Statistics

n
Mean (SD)
Median (Q1, Q3)
(Min, Max)

1128
52.4 (9.3)
55 (47, 59)
(19, 71)

Age (years)

PDC (%)
n
Mean (SD)
Median (Q1, Q3)
(Min, Max)
Number of comorbidities (n)
n
Mean (SD)
Median (Q1, Q3)
(Min, Max)
Beale code [n (%)]
1
2
3
4
5
6
7
8
9
Direct-acting Antivirals
Daklinza
Epclusa
Harvoni
Incivek
Olysio
Sovaldi
Viekira Pak
Zepatier
Gender [n (%)]

1128
95.7 (8.4)
1 (94.4, 100)
(21.4, 100)
1128
5.6 (2.8)
5 (3, 7)
(0, 17)
450 (39.9)
131 (11.6)
81 (7.2)
35 (3.1)
21 (1.9)
116 (10.3)
175 (15.5)
38 (3.4)
81 (7.2)
39 (3.5)
11 (0.1)
661 (58.6)
3 (0.0)
50 (4.4)
421 (37.3)
35 (3.1)
3 (0.0)
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Female
Male
Metro status [n (%)]
0
1
Managed care organization [n (%)]
Aetna
Anthem
Humana
Magellan
Passport
Wellcare
Race [n (%)]
White
Black
Other races or ethnicity
Not provided
Supportive care
Interferon
Ribavirin
Interferon or ribavirin

423 (37.5)
705 (62.5)
466 (41.31)
662 (58.7)
130 (11.5)
83 (7.4)
141 (12.5)
12 (1.06)
457 (40.5)
305 (27.0)
463 (41.0)
89 (7.9)
278 (24.6)
198 (17.6)
62 (5.5)
442 (39.2)
442 (39.2)

Eight DAAs were used in the study population. Although all DAAs have similar safety
and efficacy data in randomized controlled trials (Muir, 2014), compliance can be drastically
lower than in a closely monitored environment, denoting potentially substantial deviance of
outcome in actual clinical settings. The compliance statistics by DAA in Kentucky Medicaid
population are illustrated in Figure 1. Epclusa and Zepatier were used in 11 and 3 patients
respectively, but had the highest compliance rate at 90.9% and 100%. Both has similar dosing
schedules and can be used with or without ribavirin and peginterferin, just like other DAAs used
in this population. Thus, it is very likely that the high compliance presented in the population
was due to coincidence. Harvoni and Sosaldi, both of which are mainstream treatments for
chronic HCV infection, were the most heavily prescribed antivirals in Kentucky Medicaid
beneficiaries. The percentage of patients with 100% compliance with Harvoni and Sovaldi
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regimens ranges from 54%- 66%. The other DAAs were all less frequently used and poorly
managed.
Figure 1. Percentage Compliance in Kentucky Medicaid Population by DAA

Percentage of 100% Adherence, p<0.0001
90.91%

100%
90%
80%
70%
60%
50%

100%

65.20%
51.28%

50%

54.16%

33.33%

40%

31.43%

30%
20%
10%
0%

Direct-acting Antivirals
Daklinza n=39

Epclusa n=11

Harvoni n=661

Incivek n=3

Olysio n=50

Sovaldi n=421

Viekira Pak n=35

Zepatier n=3

It has been demonstrated in multiple studies that comorbidities have a major influence on
the outcome of antiviral therapy of hepatitis C (El-Zayadi, 2009; Louie, 2012). They may exert
effects through altering the course, on response of DAA, or on ribavirin/peginterferon treatment
(EL-Zayadi, 2009). No statistical significance was established in the number of comorbidities,
however, a trend towards a higher number of comorbidities among non-compliant group can be
inferred from the pie charts below in Figure 2. About 24% of members in the non-compliant
group had less than 3 comorbidities vs. 27% of compliant group. At the other end of the
spectrum are the extremely comorbid patients with 4-17 concurrent diseases. In the non-
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compliant group, 41% and 35% of the patients had 4-6 or greater than 7 comorbidities,
respectively, in comparison with 40% and 33% in the compliant group.
Figure 2. Distribution of Comorbidities in Kentucky Medicaid Population with Hepatitis C

Non-compliant Group
5, 1%

102, 23%

154, 35%

185, 41%

n=0

n=1-3

n=4-6

n>=7

Compliant Group
7, 1%

224, 33%

179, 26%

272, 40%

n=0

n=1-3

n=4-6

n>=7

Bivariate comparisons of socio-demographic and other covariates are presented in Table
2. Patients who were 100% compliant with hepatitis C therapy were compared to those who were
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not; 682 of the 1128 patients (60.4%) were found to be compliant. This allows for the assessment
of unadjusted associations of potential factors with compliance. Age (as a categorical variable),
race, MCO, DAAs used in the therapy and whether patient got multiple DAA treatments were
found to be significantly associated with medication compliance. Members in the less-than-49
age group had a considerably lower compliance than those that were 50 and above. Most patients
in the compliance group were white (42.1%) and resided metro areas (56.6%). Passport had the
greatest number of patients in the compliance group while patients with Wellcare were better
managed and more adherent (58.0% of Passport vs. 70.5% of Wellcare). To avoid uneven sample
size in the DAA category where the majority (88.5%) of scripts were in only two drug categories
(Faber & Fonseca, 2014), 8 DAA groups were downsized to 3: Harvoni, Sovaldi and other
DAAs. As anticipated, patients on 1 DAA were 1.59 times more likely to adhere to therapy than
those on 2 or more. The use of ribavirin for supportive care was also shown to have an impact,
with non-compliance group having 15.3% more patients on ribavirin than compliance group.
Table 2. Univariate Analysis of Hepatitis C Treatment Compliance

Age [n (%)]
<40
40-49
50-59
>=60
Male gender [n
(%)]
Race [n (%)]
White
Black
Other
Not Provided
Beale code [n (%)]
1-3
4-6

Non-compliant
Patients
(n = 446)

Compliant Patients
(n=682)

P value

47 (10.5)
71 (15.9)
226 (50.7)
102 (22.9)

80 (11.7)
144 (21.1)
287 (42.1)
171 (25.1)

0.03

275 (61.7)

430 (63.1)

0.64

176 (39.5)
43 (9.6)
167 (37.4)
60 (13.5)

287 (42.1)
46 (6.7)
211 (30.9)
138 (20.2)

0.003

276 (61.2)
71 (15.9)

386 (56.6)
101 (14.8)

0.06
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7-9
99 (22.2)
195 (28.6)
Metro status [n
(%)]
0
170 (38.1)
296 (43.4)
1
276 (61.9)
386 (56.6)
MCO [n (%)]
Aetna
55 (12.3)
75 (11.0)
Anthem
44 (9.9)
39 (5.7)
Humana
57 (12.8)
84 (12.3)
Magellan
8 (1.8)
4 (0.6)
Passport
192 (43.1)
265 (38.9)
Wellcare
90 (20.2)
215 (31.5)
Comorbidities (n)
5.7 ± 2.9
5.5 ± 2.8
Direct-acting
Antivirals
Harvoni
230 (46.6)
431 (59.1)
Sovaldi
193 (39.1)
228 (31.3)
Other DAAs
71 (14.4)
70 (9.6)
Multiple Treatment
0
399
635
1
47
47
Supportive Care
Ribavirin
216 (48.4)
226 (33.1)
Interferon
27 (6.1)
35 (5.1)
Ribavirin or
216 (48.4)
226 (33.1)
Interferon
Data are expressed as frequencies (column percentage) of patients.

0.08

0.0002

0.36

0.0001

0.0303
<.0001
0.5068
<.0001

The bivariate analysis between 31 comorbidities and compliance, arranged from the
highest to the lowest frequency, is reported in Table 3. Patients with chronic kidney disease
(CKD), depression and substance use disorder (SUD) were linked to the highest rate of
compliance. This finding in patients with SUD is not unexpected, given that opioid treatment
programs are structured to provide medical supervision over opioid detoxication and the
administration of all other prescribed medications, including antivirals for hepatitis C (McCanceKatz & Valdiserri, 2015). None of the disease states but liver fibrosis/cirrhosis was found to be
statistically significant in relation to compliance. Although myocardial infarction, liver cancer,
colorectal cancer, prostate cancer, osteoporosis and liver transplant were marginally significant
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(p-value <=0.1), they were excluded from the final multi-variate logistic regression model
because of their tendency to lead to inaccurate conclusions (King & Zeng, 2001).
Table 3. Bivariate Associations Between Comorbidities with Hepatitis C Therapy Compliance
Comorbidity
Cardiovascular disease
Hypertension
Hyperlipidemia
Ischemic heart disease
Heart failure
Stroke/Transient heart attack
Atrial fibrillation
Myocardial infarction
Substance use disorder
Liver fibrosis/cirrhosis
Rheumatoid arthritis
Depression
COPD/Bronchiectasis
Asthma
Anemia
Chronic kidney disease
Diabetes
Hyperthyroidism
Cataract
Benign prostatic hyperplasia
Cancer
Liver cancer
Breast cancer
Colorectal cancer
Lung cancer
Prostate cancer
Endometrial cancer
Osteoporosis
Glaucoma
Liver transplant
Alzheimer’s and related
diseases
Hip/Pelvic fracture
Autism sectrum

869
800
399
171
79
59
28
26
836
637
543
511
480
374
274
273
268
117
106
80
72
41
9
9
9
7
1
46
41
22

Percentage compliant
(%)
60.1
60.1
59.4
57.9
60.8
57.6
53.6
42.3
61.1
57.3
57.8
61.3
61.0
60.7
57.7
61.5
60.1
56.4
60.4
58.8
51.4
46.3
44.4
88.9
55.6
28.6
100.0
73.9
70.7
40.9

Odds
Ratio
0.93
0.95
0.93
0.88
1.01
0.88
0.75
0.47
1.46
0.74
0.81
1.06
1.04
1.01
0.86
1.06
0.98
0.83
1.00
0.93
0.67
0.55
0.52
5.28
0.82
0.26
/
1.90
1.61
0.45

P
value
0.62
0.72
0.59
0.46
0.96
0.65
0.45
0.06
0.44
0.01
0.08
0.62
0.73
0.91
0.28
0.68
0.88
0.34
0.99
0.75
0.10
0.06
0.32
0.08
0.76
0.08
0.42
0.06
0.17
0.06

18

61.1

1.02

0.95

9
1

44.4
0.0

0.52
/

0.32
0.22

Frequency
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Based on the result from the bivariate analysis in Table 2 and Table 3, the variables
proposed for the multi-variate logistic regression model with backward elimination included age
(as a categorical variable), race, MCO, DAAs, whether patient got multiple DAA treatments
(multiple treatment) and use of ribavirin. To fully rule out the possibility of high-frequency
comorbidities playing a role in compliance, the most common top 10 comorbidities were also
incorporated into model: CVD, SUD, liver fibrosis/cirrhosis, rheumatoid arthritis, depression,
COPD/Bronhiectasis, asthma, anemia, CKD and Diabetes. The statistics for factors that
remained after backward elimination were recalculated in the final regression model. As a result,
five variables were ultimately shown to be independently associated with compliance. These
include group with age equal to or greater than 60 in comparison with those in 50-59, liver
fibrosis/cirrhosis, Aetna, Anthem, Humana and Passport with Wellcare as the reference MCO
group, Anthem with Humana as the reference group, the use of ribavirin and being treated with
more than 1 DAAs. Having rheumatoid arthritis and taking Sovaldi both approach but fell short
of significance (p=0.05). Adjusting for the other covariates, members with an age greater than 60
were estimated to have 1.434 [95% CI: (1.045, 1.968)] times of the odds of achieving
compliance than in those who were between age 50-59. Diagnosis of liver fibrosis or cirrhosis
had 0.74 [95% CI: (0.57, 0.96)] times the odds of compliance of those who did not have this
disease. Furthermore, lower odds of compliance were also found to be conditionally associated
with the MCO affiliation. Specifically, the odds of compliance were estimated to be 0.58 [95%
CI: (0.37, 0.89)], 0.35 [95% CI: (0.21, 0.58)], 0.64 [95% CI: (0.42, 0.99)] and 0.55 [95% CI:
(0.40, 0.76)] respectively for patients managed by Aetna, Anthem, Humana and Passport, as
compared with patients by Wellcare. Compared to those of Humana (0.55 [95% CI: (0.31,
0.96)]), beneficiaries served by Anthem were about half as compliant, indicating that disparity of
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drug utilization and adherence management were present in the Kentucky Medicaid managed
care organizations. Members who had had more than one DAAs in the two-year study period
were estimated to have 0.50 [95% CI: (0.29, 0.86)] times of the odds of achieving compliance
than in those who had one. Finally, the odds of being compliant is reduced significantly by
61.6% [95% CI: (0.26, 0.58)] with ribavirin as supportive therapy than those only on DAAs.
Table 4. Patient characteristics independently associated with hepatitis C therapy compliance
Reference
p-value Odds ratio 95% Confidence Interval
Age >= 60
50 <= Age <= 59 0.0257
1.434
1.045– 1.968
Liver Fibrosis/Cirrhosis
No
0.0152
0.741
0.570 – 0.963
MCO - Aetna
Wellcare
0.0134
0.575
0.371 – 0.892
MCO - Anthem
Wellcare
<.0001
0.351
0.211 – 0.584
MCO - Humana
Wellcare
0.0429
0.641
0.417 – 0.986
MCO - Passport
Wellcare
0.0003
0.554
0.403 – 0.761
MCO - Anthem
Humana
0.0356
0.547
0.311 – 0.960
Multiple DAAs
No
0.0128
0.502
0.291 – 0.864
Rheumatoid Arthritis
No
0.0706
0.789
0.610 – 1.020
Ribavirin
No
<.0001
0.384
0.256 – 0.576
Sovaldi
No
0.0818
1.485
0.951 – 2.317
DISCUSSION
This is the first retrospective observational study that analyzes compliance influencing
factors in HCV infected, state Medicaid patients taking new generation hepatitis C drugs. There
are several factors that seem to influence adherence in this population. Older age above 60 has a
positive impact on adherence, while “liver fibrosis/cirrhosis” was found to impair compliance
considerably. Disease management between MCOs also differs significantly. Gender, race,
county of residency, number of comorbidities, comorbidities other than liver fibrosis or cirrhosis
and whether patients received more than one DAA medication treatment were not shown to be
relevant to compliance.
Because of the recent introduction of DAAs up to today and the unique nature of the
study population, our finding on DAA compliance can hardly be compared with research

17
findings in general HCV infected patients taking ribavirin and/or interferons, in terms of both
overall adherence rate and contributing factors of compliance. A prospective cohort study in
2010 in 1860 CHC patients initiating ribavirin and peginterferon revealed that only 38% of
patients reported strict adherence to the regimen, defined as full-dose and persistent therapy as
initially intended by physician (Marcellin, 2011). This stark comparison to 60.4% strict
adherence rate with DAAs demonstrated the collaborative efforts from physicians, payers and
patients to ensure treatment success. They found that HIV co-infection, no drug use during
follow-up, genotype 3 and treatment naïve were independent predictors of adherence. A systemic
review conducted in 2010 on factors influencing adherence in hepatitis-C infected patient
concluded that factors, including psychiatric disorders, depression, higher ribavirin dose,
negatively affected compliance and HIV co-coinfection and hemoglobin level seemed to play a
positive role in promoting compliance (Mathes, Antoine, & Pieper, 2014).
In our patient population, many of these factors were either near identical at baseline or
unidentifiable in prescription claims. For example, Kentucky Medicaid’s FFS provider,
Magellan, requires that patients with a history of psychosis, schizophrenia, bipolar disorder or
schizoaffective disorder are ineligible for one of most commonly prescribed and evidencesupported regimen in hepatitis C genotype 1 infection (Sovaldi, interferon alfa and weight-based
ribavirin combination treatment), unless they are on therapy and compliant with this therapy as
reflected by pharmacy paid claim histories (Fried et al, 2013).
Many factors determine difference in compliance. These include internal factors, such as
age, sex, race, hepatitis C genotype, comorbidities, all of which are impossible to change at the
time of treatment. External factors, on the other hand, include all the environmental
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circumstances that can be optimized throughout the treatment course. Treatment regimen,
physicians and MCO enrollment are all examples of external factor.
Age seems to be an irrelevant determinant of compliance in our study population until
patients reach the age of 60, when it starts to show a marked positive effect. This impact is not
found in any previous studies done on hepatitis C patients using ribavirin and interferon.
However, as counterintuitive as it may sound, increased likelihood of adherence with age has
been demonstrated in multiple studies that investigated the determinants of adherence with
antipsychotic medications (Gilmer et al, 2004) and rheumatoid arthritis (Viller et al, 1999). The
same result was also seen in Medicaid population with other medical concerns, such as
hypertension (Monane et al, 1996; Bailey, Lee, Somes, & Graham, 1996), diabetes using
sulfonylurea regimen (Sclar et al, 1999) and hyperlipidemia (Avon et al, 1998). Why older adults
are more compliant is unknown, but it may be due to a slower paced life, better communication
with health care professionals and decreased financial pressure. Avon specifically proposed that
the number of prescribed medications, rather than old age per say, is the risk factor for
noncompliance. This supports the connection of multiple DAA treatment with decrease
compliance in our study.
The study showed a link between both liver disease and rheumatoid arthritis and
compliance. The lower compliance rate among patients with liver fibrosis or cirrhosis was well
predicted in the clinical trials of DAAs. A systemic review of hepatitis C treatment published in
2014 on Nature outlined the poor response rate of DAAs in patients with HCV genotype 2:
patients with cirrhosis or fibrosis responded less well to Sovaldi + pegylated interferon + weightbased ribavirin regimen (80% vs 92%) or Sovaldi + weight-based ribavirin alone therapy (54%
vs 79%) (Kohli, Shaffer, Sherman, & Kottilil, 2014) than patients without it. The incomplete or
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slow virologic response leads to a lack of motivation in physicians and patients, decreased
adherence and early discontinuation of DAAs. In comparison, the link between rheumatoid
arthritis and adherence is more straightforward. Rheumatoid arthritis is a chronic inflammatory
disease affecting joints, causing stiffness, weakness, painful swelling and decreased range of
motion (Arthritis Foundation, n.d.), thus directly hindering the medication taking behavior.
The high cost of these medications helps classify hepatitis C antivirals as specialty
medications. Regardless of whether a certain DAA is on the Medicaid Preferred Drug List (PDL)
or not, it is required that physicians file prior authorization forms and ensure that diagnostic and
therapeutic criteria are met before a DAA is approved for initiation of the first cycle (Aetna
Better Health of Kentucky, 2017; Anthem Blue Cross Blue Shield, 2017; Humana CareSource,
2017; Magellen Medicaid, 2017; Passport Health Plan, 2017; Wellcare of Kentucky, 2017). Once
approved, the copay is comparable between DAAs and usually falls below $10 for a 28-day
supply (Kentucky Cabinet for Health and Family Services (KCHFS), n.d.;). Instead, factors that
tend to hinder treatment compliance in Medicaid population are typically adverse events or
regimen complexity (in terms of dosing frequency and polypharmacy).
Ribavirin is sometimes used as supportive care to increase rates of sustained virologic
response (SVR) or to shorten treatment duration without altering the rates of SVR (Pawlotsky,
2014). Pegylated interferon are also utilized in combination with DAAs to induce specific and
nonspecific immune response against HCV and inhibit viral replication. They both have
undesirable adverse effect, but ribavirin is more often associated with central nervous system,
gastrointestinal, hematologic and dermatologic toxicities, such as headache, nausea, depression,
hepatic toxicity, anemia, neutropenia, diarrhea and rash, thus leading to premature treatment
discontinuation (Genetech, 2002).
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Harvoni and Sovaldi have relatively high compliance rates among the eight DAAs used
in this population. Both are dosed once daily, so the differences in compliance between the two
usually lays in dosing complexity. Harvoni is commonly used as a single agent dosed daily in
patients in chronic HCV infection without ribavirin, unless the patient is also a liver transplant
recipient, while Sovaldi is often prescribed with ribavirin and interferon for genotype 1 infection
(most of our population). However, after controlling for the use of ribavirin and interferon in the
final model, Sovaldi was significantly more appealing to our patient population than other
DAAs. The underlying mechanism for this huge variance is not clear. It can be due to the severe
adverse events recently reported by the Institute for Safe Medication Practice. In the 12 months’
FDA Adverse Event Reporting System (FAERS) data between Novermber 2015 – October 2016,
Harvoni was the primary suspect for 116 liver failures, 91 cases were correlated with Sovaldi and
120 cases with Viekira pak (Quarter Watch, 2017). The exact association between adverse
effects of DAAs and compliance should be further investigated in future studies. At the lowest
compliance rate (31.4% and 33.3% respectively), Incivek and Viekira Pak each have a more
frequent and complex dosing schedule. Incivek was discontinued in the US market for more than
a year, but it was previously dosed at twice a day with or without ribavirin/peginterferon for
chronic HCV infection other than genotype 1. Viekira Pak, on the other hand, is a copackaged
product containing ombitasvir, paritaprevir and ritonavir as a fixed-dose combination tablet and
dasabuvir as an individual tablet. Patients are supposed to take two combination tablets in the
morning and one dasabuvir tablet twice daily.
Even though patients with Wellcare were shown to be more compliant than all other
MCOs contracted with Kentucky Medicaid, it is not well understood why this is the case.
Kentucky Medicaid issues a “Guide to choosing a Medicaid Health Plan” to help (potential)
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members choose among Magellan, Aetna, Anthem, Huamna, Passport and Wellcare every year
based on individual needs. The latest issue for 2017 indicated that Wellcare exceled in “Getting
child care quickly”, “21 and under dental visits”, “Getting adult care quickly” and “Adult overall
satisfaction with health plan”. The connection between these performances and hepatitis C
medication compliance management, however, is unknown. Wellcare, together with Coventry,
Kentucky spirit, were the three health plans initially enrolling Medicaid beneficiaries when the
implementation of Medicaid Managed Care was started in November 1, 2011. Additional
managed care plans, Humana, Passport and Anthem, didn’t begin to provide services to the
entire Medicaid population until July 1, 2017 (Marton et al, 2016). With Wellcare being more
experienced with the Kentucky Medicaid population, they are better at therapy monitoring,
building appropriate clinical criteria and efficient communication with physicians.
The result of this study reflects the hepatitis C medication compliance in contiguously
enrolled Kentucky Medicaid patients, but may not apply to overall Medical or general patients
on DAAs. To remain consistent with national standard measurement for disease management
(NCQA, 2008), 302 members were excluded from analysis due to excessive coverage gap. As a
result, they either fall into an uninsured state of having incomes above Medicaid eligibility limits
but below the lower limit for marketplace premium tax credits, or bumped to receive
marketplace subsidies. Little data can be found on these people that fell into the gap in Kentucky,
but it is clear that their quality of care can be severely compromised. In comparison to study
population, this subgroup of Medicaid members is more likely to face challenges of higher copay, less close treatment monitoring and experience more treatment interruptions and
coordination for transition of care. Chronic HCV patients of the same economic status outside
Medicaid can be drastically distinctive as well. A study in 2010 that looked at the demographic
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and health characteristics of the population who will be eligible for Medicaid under Affordable
Care Act (ACA) found that both the nondisabled and the disabled adults who were currently
enrolled in Medicaid were more likely to have poor general health, mental health and more
chronic conditions on average relative to both uninsured and privately insured adults with
incomes below 138% of the federal poverty level (FPL) (Holanhan, Kenney, & Palletier, 2010).
They all imply that the resulted compliance in this study might be an optimistic estimation of
DAA compliance in overall Medicaid patients and an underestimation of that in general
population.
There are several limitations in this study that are worth noting. Our data were derived
from Kentucky Medicaid outpatient pharmacy claims. They provided very limited information
on the severity of HCV infection, comorbidities (HIV or Hepatitis B coinfections), prior
treatment history and social history. Although having these data could greatly add to the
predictable accuracy of our study, it takes extensive time and manpower to manually go over all
the prior authorization claims for all the DAAs and collect those data in a uniform format. On the
other hand, public information on MCO’s prescription drug management, especially for specialty
drugs, is nonexistent. Complete clinical criteria to get prior authorization approval are private
information and not shared with the public. If the Kentucky Medicaid clinical criteria for all the
MCOs and FFS could be accessed, we could determine the root cause for the difference in
compliance.
In conclusion, access to hepatitis C antivirals does not come easily. Aside from the
financial shackles that all health insurance provider face, patients must meet as many as more
than 20 clinical criteria to be eligible for DAA. Once access is granted, patients are entitled to
therapy for once in their lifetime unless resistance or intolerance develops during the treatment
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course. Therefore, it is not surprising to see payers closely monitor lab test and treatment course,
require prior authorization every step of the way and approve therapies by cycle. If patients could
be screened for characteristics that have been known to predispose them to noncompliance and
manage them alongside hepatitis C, we could make a huge impact on hepatitis C treatment
outcome.
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